IL152891A0 - Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids - Google Patents

Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids

Info

Publication number
IL152891A0
IL152891A0 IL15289101A IL15289101A IL152891A0 IL 152891 A0 IL152891 A0 IL 152891A0 IL 15289101 A IL15289101 A IL 15289101A IL 15289101 A IL15289101 A IL 15289101A IL 152891 A0 IL152891 A0 IL 152891A0
Authority
IL
Israel
Prior art keywords
tetrahydrocannabinol
cell proliferation
delta
methods
decreasing cell
Prior art date
Application number
IL15289101A
Other languages
English (en)
Original Assignee
Atlantic Technology Ventures I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlantic Technology Ventures I filed Critical Atlantic Technology Ventures I
Publication of IL152891A0 publication Critical patent/IL152891A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
IL15289101A 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids IL152891A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
PCT/US2001/015916 WO2001087295A1 (fr) 2000-05-17 2001-05-17 Procedes permettant de reduire la proliferation cellulaire fondes sur des acides (3r, 4r)-δdelta8-tetrahydrocannabinol-11-oiques

Publications (1)

Publication Number Publication Date
IL152891A0 true IL152891A0 (en) 2003-06-24

Family

ID=22760084

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15289101A IL152891A0 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids
IL15289201A IL152892A0 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
IL152892A IL152892A (en) 2000-05-17 2002-11-17 Use of cannabinoids for the preparation of drugs for the treatment or prevention of cell culture diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL15289201A IL152892A0 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
IL152892A IL152892A (en) 2000-05-17 2002-11-17 Use of cannabinoids for the preparation of drugs for the treatment or prevention of cell culture diseases

Country Status (13)

Country Link
US (2) US6448288B1 (fr)
EP (2) EP1307186A4 (fr)
JP (2) JP2003533478A (fr)
CN (2) CN1273123C (fr)
AT (1) ATE406156T1 (fr)
AU (5) AU2001263217A1 (fr)
CA (2) CA2408961A1 (fr)
DE (1) DE60135557D1 (fr)
HU (2) HUP0700039A2 (fr)
IL (3) IL152891A0 (fr)
NZ (2) NZ523028A (fr)
RU (2) RU2272620C2 (fr)
WO (3) WO2001087295A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103410A1 (fr) 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions de procedes et articles de fabrication destines a moduler la croissance osseuse
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
JP2007501279A (ja) * 2003-05-20 2007-01-25 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデイション カンナビノイド誘導体、その製造方法、および使用
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2006065793A2 (fr) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Traitement de la cystite interstitielle au moyen d'acides (6ar,10ar)-?8-tetrahydrocannabinol-11-oiques
WO2006065792A2 (fr) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Traitement de la cystite interstitielle au moyen d'analogues cannabinoides
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
KR20080063800A (ko) * 2005-09-29 2008-07-07 에이엠알 테크놀로지, 인크. 델타-9-테트라히드로칸나비놀의 제조 방법
WO2007047010A2 (fr) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Utilisations antiemetiques d'analogues cannabinoides
WO2007055806A1 (fr) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Utilisation antiemetique des acides (3r,4r)-δ8-tetrahydrocannabinol-11-oiques
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
CA2707671C (fr) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg Derives d'oxindole a double substitution en positions 5 et 6 et leur utilisation pour traiter des maladies liees a la vasopressine
BRPI0820668A2 (pt) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
WO2010009775A1 (fr) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Dérivés d'oxindole à substitution carbamate et utilisation de ceux-ci pour traiter des maladies dépendant de la vasopressine
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
WO2010138600A2 (fr) 2009-05-29 2010-12-02 Abbott Laboratories Compositions pharmaceutiques utilisées dans le traitement de la douleur
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
AU2018311966A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Benzo[b]thiophene sting agonists for cancer treatment
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (es) * 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.

Also Published As

Publication number Publication date
AU2001263217A1 (en) 2001-11-26
HUP0700038A2 (en) 2007-05-02
CN1452485A (zh) 2003-10-29
JP2003533479A (ja) 2003-11-11
IL152892A0 (en) 2003-06-24
CA2409005A1 (fr) 2001-11-22
EP1307186A4 (fr) 2005-10-19
EP1307186A1 (fr) 2003-05-07
NZ523028A (en) 2004-09-24
NZ523029A (en) 2004-11-26
EP1307188A4 (fr) 2005-07-06
JP2003533478A (ja) 2003-11-11
AU2001261695B2 (en) 2005-06-16
US6448288B1 (en) 2002-09-10
WO2001087295A8 (fr) 2003-04-10
US20020022653A1 (en) 2002-02-21
ATE406156T1 (de) 2008-09-15
AU2001264680B2 (en) 2006-09-14
EP1307188B1 (fr) 2008-08-27
US6914072B2 (en) 2005-07-05
DE60135557D1 (de) 2008-10-09
EP1307188A1 (fr) 2003-05-07
WO2001087295A1 (fr) 2001-11-22
CN1447685A (zh) 2003-10-08
WO2001087297A1 (fr) 2001-11-22
CN1227007C (zh) 2005-11-16
CN1273123C (zh) 2006-09-06
AU6468001A (en) 2001-11-26
CA2408961A1 (fr) 2001-11-22
RU2272620C2 (ru) 2006-03-27
AU6169501A (en) 2001-11-26
WO2001087296A1 (fr) 2001-11-22
RU2273476C2 (ru) 2006-04-10
US20040225011A1 (en) 2004-11-11
IL152892A (en) 2010-06-30
HUP0700039A2 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
AU6169501A (en) Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
AU2001273728A1 (en) Arrangement for connecting planar components
AU2002224893A1 (en) Method for producing a part and device for carrying out this method
EP1509793A4 (fr) Combineur/diviseur de faisceau a polarisation optique
AU2001287156A1 (en) Treatment for high pressure bleeding
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
AU2002211663A1 (en) Nf-$g(k)b inhibitors
MXPA05002489A (es) Composiciones para el cuidado personal basadas en alcohol ramificado.
AU4433700A (en) Prolyl endopeptidase inhibitor
AU2001283161A1 (en) Pumping arrangement for fiber amplifiers
AU2003216901A1 (en) Polarizing beamsplitter
HUP0304079A3 (en) Carcass alignment system for carcass splitter
AU2002331595A1 (en) Novel vasoconstrictor cannabinoid analogs
AU2002351021A1 (en) Kit for reducing aching caused by pde-v inhibitors
AU3683700A (en) Database organization for increasing performance by splitting tables
AU2001263786A1 (en) Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AU2001265759A1 (en) Method for the highly parallel analysis of polymorphisms
AU2002220346A1 (en) Method for determination of the fertility of mammals, in particular of man
AU2002243647A1 (en) Novel mesogens
AU2001268268A1 (en) Latin draw poker
AU2002310556A1 (en) 2-adamantyl-4,6-diamino-1,2-dihydro-1-aryl-1,3,5-triazine derivatives as cell prolifiration inhibitors
MXPA03005400A (es) Metodo para preparacion de 11 (12)-pentadecen-15-olidos.
AU2003227748A1 (en) Agents for dyeing keratin fibers, containing 4-amino-biphenyl-3-ol-derivatives
AU2002315472A1 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors